A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, et al. Leukemia 2024;38:58-66.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, et al. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia 2024;38:58-66.
PMID: 37935977